<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858622</url>
  </required_header>
  <id_info>
    <org_study_id>SMS2016-1</org_study_id>
    <nct_id>NCT02858622</nct_id>
  </id_info>
  <brief_title>Dual Transversus Abdominis Plane Block in Pediatric Renal Transplant: Effect on Pain Control</brief_title>
  <official_title>Unilateral Dual Transversus Abdominis Plane Block in Pediatric Renal Transplant: A Randomized Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alleviating pain in children undergoing renal transplant is extremely challenging. Large
      incisions as those of renal transplant (Gibson's incision) require special techniques of pain
      control that don't affect hemodynamics or renal function. Since the transplant incision
      doesn't cross midline; a dual-TAP block is thought to be effective in providing pain control
      in such procedure as it will anesthetize the dermatomes T6-T12, the muscles of the anterior
      abdominal wall together with the underlying parietal peritoneum.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>total dose of rescue analgesia</measure>
    <time_frame>from the time of transfer of the patient to the intensive care unit at one hour intervals for 24 hours</time_frame>
    <description>pethidine given as rescue analgesia postoperative.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain scoring system (objective behavioural pain score)</measure>
    <time_frame>from the time of transfer to the nephrology ICU, every hour for the first 24 hours postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood pressure</measure>
    <time_frame>from the induction of anesthesia till end of surgery at half an hour intervals average duration is 4 hours</time_frame>
    <description>measure systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative blood pressure</measure>
    <time_frame>from the time of transfer of the patient to the intensive care unit at one hour intervals for 24 hours</time_frame>
    <description>record systolic and diastolic blood pressure every hour for the first 24 hours postoperative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative heart rate</measure>
    <time_frame>from the time of transfer of the patient to the intensive care unit at one hour intervals for 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraoperative heart rate</measure>
    <time_frame>from the induction of anesthesia till end of surgery at half an hour intervals average duration is 4 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>dual TAB group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>22 patients will receive unilateral dual transversus abdominis plane (TAB) block USING bupivacaine 0.25% at a dose of 2 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>22 patients who will not receive dual TAB block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine</intervention_name>
    <description>bupivacaine 0.25% at a dose 2 mg/kg in the transversus abdominis plane</description>
    <arm_group_label>dual TAB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pethidine</intervention_name>
    <description>pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia</description>
    <arm_group_label>dual TAB group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>perfalgan</intervention_name>
    <description>intravenous paracetamol</description>
    <arm_group_label>dual TAB group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fentanyl</intervention_name>
    <arm_group_label>dual TAB group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  3-18 years

          -  end stage renal disease

          -  no known allergy to bupivacaine

          -  both sexes

        Exclusion Criteria:

          -  known allergy to bupivacaine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherif M Soaida, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherif M Soaida, M.D.</last_name>
    <email>sherif_soaida@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of medicine, Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherif M Soaida, M.D.</last_name>
      <email>sherif_soaida@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <last_update_submitted>December 6, 2016</last_update_submitted>
  <last_update_submitted_qc>December 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Sherif Mohamed Abd el moneim Soaida, MD</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>renal transplant</keyword>
  <keyword>pain</keyword>
  <keyword>dual TAB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Meperidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

